Arbutus Biopharma Corp Employee Stock Ownership Plan (ESOP), Compensation Expense
Arbutus Biopharma Corp (ABUS) reported Employee Stock Ownership Plan (ESOP), Compensation Expense of $100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense · last filed 2026-03-23
CAD
| Period end | Employee Stock Ownership Plan (ESOP), Compensation Expense 12 month |
|---|---|
| 2012-12-31 | 981.66K CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | 626.12K CAD 20-F · filed 2013-03-27 |
| 2010-12-31 | 650.62K CAD 20-F · filed 2013-03-27 |
USD
| Period end | Employee Stock Ownership Plan (ESOP), Compensation Expense 3 month | Employee Stock Ownership Plan (ESOP), Compensation Expense 6 month | Employee Stock Ownership Plan (ESOP), Compensation Expense 9 month | Employee Stock Ownership Plan (ESOP), Compensation Expense 12 month | Employee Stock Ownership Plan (ESOP), Compensation Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $100.00K 10-K · filed 2026-03-23 | ||||
| 2024-12-31 | $100.00K 10-K · filed 2026-03-23 | ||||
| 2023-12-31 | $100.00K 10-K · filed 2025-03-27 | $200.00K 10-K · filed 2024-03-05 | |||
| 2022-12-31 | $200.00K 10-K · filed 2024-03-05 | ||||
| 2021-12-31 | $300.00K 10-K · filed 2023-03-02 | ||||
| 2020-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $200.00K derived: sum of 2 quarters · filed 2022-03-03 | $200.00K 10-K · filed 2022-03-03 | ||
| 2020-09-30 | $100.00K 10-Q · filed 2020-11-05 | $100.00K 10-Q · filed 2020-11-05 | |||
| 2015-12-31 | $22.09M 10-K · filed 2016-03-09 | ||||
| 2014-12-31 | $3.28M 10-K · filed 2016-03-09 | $3.28K 10-K · filed 2015-03-13 | |||
| 2013-12-31 | $903.00K 10-K · filed 2016-03-09 | $903.00K 6-K · filed 2014-03-06 | |||
| 2012-12-31 | $982.00 10-K · filed 2015-03-13 | $982.29K 6-K · filed 2014-03-06 | |||
| 2011-12-31 | $633.45K 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |